DE69836268D1 - Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen - Google Patents

Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen

Info

Publication number
DE69836268D1
DE69836268D1 DE69836268T DE69836268T DE69836268D1 DE 69836268 D1 DE69836268 D1 DE 69836268D1 DE 69836268 T DE69836268 T DE 69836268T DE 69836268 T DE69836268 T DE 69836268T DE 69836268 D1 DE69836268 D1 DE 69836268D1
Authority
DE
Germany
Prior art keywords
immune
polydimethylsiloxane
collagen
administration form
carrier substances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69836268T
Other languages
English (en)
Other versions
DE69836268T2 (de
Inventor
Keiji Fujioka
Akihiko Sano
Shunji Nagahara
Roy Brandon
Donald Nash
Shari Lofthouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Koken Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
University of Melbourne
Koken Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Melbourne, Koken Co Ltd, Sumitomo Dainippon Pharma Co Ltd filed Critical University of Melbourne
Application granted granted Critical
Publication of DE69836268D1 publication Critical patent/DE69836268D1/de
Publication of DE69836268T2 publication Critical patent/DE69836268T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69836268T 1997-05-19 1998-05-18 Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen Expired - Lifetime DE69836268T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP14592097 1997-05-19
JP14592097 1997-05-19
JP14246197 1997-05-30
JP14246197 1997-05-30
JP31628597 1997-10-30
JP31628597 1997-10-30
PCT/JP1998/002172 WO1998052605A1 (en) 1997-05-19 1998-05-18 Immunopotentiating composition

Publications (2)

Publication Number Publication Date
DE69836268D1 true DE69836268D1 (de) 2006-12-07
DE69836268T2 DE69836268T2 (de) 2007-05-31

Family

ID=27318454

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836268T Expired - Lifetime DE69836268T2 (de) 1997-05-19 1998-05-18 Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen

Country Status (12)

Country Link
US (1) US20110217366A1 (de)
EP (1) EP0983088B1 (de)
KR (1) KR100574216B1 (de)
CN (1) CN1150033C (de)
AT (1) ATE343396T1 (de)
AU (1) AU740133B2 (de)
BR (1) BR9809656A (de)
CA (1) CA2290696C (de)
DE (1) DE69836268T2 (de)
NZ (1) NZ500967A (de)
TW (1) TW586934B (de)
WO (1) WO1998052605A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055455A (en) 1988-09-28 1991-10-08 Brigham And Women's Hospital Capsular polysaccharide adhesin antigen, preparation, purification and use
US7252828B2 (en) 1998-07-15 2007-08-07 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
AUPP646798A0 (en) * 1998-10-12 1998-11-05 Csl Limited Fibrin glue as a biological adjuvant
AU3004700A (en) * 1999-02-24 2000-09-14 University Of Iowa Research Foundation, The Methods and compositions for delivery of and specific immune response to nucleotide expression systems
US7265199B2 (en) 2000-04-11 2007-09-04 Celonova Biosciences Germany Gmbh Poly-tri-fluoro-ethoxypolyphosphazene coverings and films
JP2002003396A (ja) * 2000-06-20 2002-01-09 Adaputogen Seiyaku Kk 免疫増強剤及びその製造方法
US9080146B2 (en) 2001-01-11 2015-07-14 Celonova Biosciences, Inc. Substrates containing polyphosphazene as matrices and substrates containing polyphosphazene with a micro-structured surface
DE10100961B4 (de) 2001-01-11 2005-08-04 Polyzenix Gmbh Körperverträglicher Werkstoff und mit diesem Werkstoff beschichtetes Substrat für die Züchtung von Zellen und künstlichen aus Zellen aufgebauten oder gewachsenen organischen Implantaten
WO2003015719A1 (de) 2001-08-17 2003-02-27 Polyzenix Gmbh Vorrichtung auf basis von nitinol mit polyphosphazenüberzug
US20050129776A1 (en) 2002-05-03 2005-06-16 Inserm Microparticles supporting cells and active substances
AU2003290867A1 (en) 2002-11-12 2004-06-03 The Brigham And Women's Hospital, Inc. Methods and products for treating staphylococcal infections
CN100351260C (zh) 2002-11-12 2007-11-28 布赖汉姆妇女医院 葡萄球菌感染的多糖疫苗
AU2003901008A0 (en) * 2003-03-04 2003-03-20 Anadis Ltd Composition for the treatment and prevention of bacterial infections
EP2439213B1 (de) 2004-04-21 2018-12-12 The Brigham and Women's Hospital, Inc. Poly-N-acetylglucosamin (PNAG/DPNAG)-bindenden Antikörper und Verwendungsverfahren dafür
CA2583061C (en) 2004-10-06 2015-02-17 Kwang Guan Tay Antibody production method
US9107850B2 (en) 2004-10-25 2015-08-18 Celonova Biosciences, Inc. Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
US20210299056A9 (en) 2004-10-25 2021-09-30 Varian Medical Systems, Inc. Color-Coded Polymeric Particles of Predetermined Size for Therapeutic and/or Diagnostic Applications and Related Methods
US9114162B2 (en) 2004-10-25 2015-08-25 Celonova Biosciences, Inc. Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same
EP2089071B1 (de) 2006-10-10 2011-12-21 CeloNova Biosciences, Inc. Bioprothetische herzklappe mit polyphosphazen
JP2010518917A (ja) 2007-02-19 2010-06-03 マリン ポリマー テクノロジーズ，インコーポレーテッド 止血組成物及び治療法
BRPI0916365A2 (pt) 2008-07-21 2018-05-02 Brigham & Womens Hospital Inc métodos e composições relacionados aos oligossacarídeos de glicosina beta-1,6 sintéticos
CA2764424C (en) * 2009-06-04 2019-12-31 National Institute Of Advanced Industrial Science And Technology Vaccine for mycoplasma infection
CN101690810B (zh) * 2009-10-21 2011-08-17 辽宁益康生物股份有限公司 一种鸡新城疫、传染性支气管炎、减蛋综合征、禽流感四联灭活疫苗佐剂及其制备方法
KR101518866B1 (ko) * 2013-08-08 2015-05-21 연세대학교 원주산학협력단 락토바실러스 플랜타룸 및 이의 용도
KR101647299B1 (ko) * 2015-04-10 2016-08-10 성균관대학교산학협력단 암 백신 조성물 및 이의 제조 방법

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3469003A (en) * 1966-04-01 1969-09-23 Haver Lockhart Lab Inc Injectable reconstituted collagen fluid adjuvant for vaccines and other drugs
JPS5540568B2 (de) * 1972-10-05 1980-10-18
US3958025A (en) * 1972-10-06 1976-05-18 Livingston Virginia W C Abscisic acid tablets and process
US4488911A (en) * 1975-10-22 1984-12-18 Luck Edward E Non-antigenic collagen and articles of manufacture
US4277249A (en) * 1979-10-15 1981-07-07 Nichols Institute Mammalian Somatomedin measurement
US4423895A (en) * 1981-04-22 1984-01-03 Mosley Jr Thomas C Dead-bolt-type locking means, and an assembly thereof
FR2516927B1 (fr) * 1981-11-26 1986-05-23 Merieux Fond Procede de preparation industrielle de materiaux collageniques a partir de tissus placentaires humains, materiaux collageniques humains obtenus, leur application comme biomateriaux
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
JPS59164723A (ja) * 1983-03-10 1984-09-17 Koken:Kk 再生コラーゲンフイブリルを含有する基質及びその製造方法
DE3331627A1 (de) * 1983-09-01 1985-03-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verfahren zur immunologischen bestimmung fuer proteine in koerperfluessigkeiten, unter verwendung monovalenter antikoerperfragmente
US4855134A (en) * 1983-10-14 1989-08-08 Sumitomo Pharmaceuticals Company, Limited Sustained-release preparation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
US5385738A (en) * 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
CA1277601C (en) * 1985-12-27 1990-12-11 Shigeji Sato Method for producing sustained release formulation
EP0230654B1 (de) * 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Arzneimittel mit verzögerter stossweiser Freisetzung
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
EP0402955B1 (de) * 1986-07-30 1994-03-09 Sumitomo Pharmaceuticals Company, Limited Verabreichungsinstrument zum Einführen von festen Medikamenten
JPS6447952A (en) * 1987-05-06 1989-02-22 Saibaafuruua Inc Immunoassay, reagent used therefor and making thereof
JPH0720483B2 (ja) * 1987-05-29 1995-03-08 住友製薬株式会社 高粘度糊状組成物成形体の乾燥法
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US5236704A (en) * 1988-01-28 1993-08-17 Sumitomo Pharmaceuticals Co., Ltd. Controlled release formulation
WO1989011862A1 (en) * 1988-05-31 1989-12-14 Biotechnology Australia Pty. Ltd. Actions of hormones
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5244672A (en) * 1988-12-02 1993-09-14 Coletica Composition containing liposomes stabilized by a stabilizing support based on atelocollagen and glycosaminoglycans
US5395620A (en) * 1989-01-31 1995-03-07 Coletica Biodegradable microcapsules having walls composed of crosslinked atelocollagen and polyholoside
KR0185973B1 (ko) * 1989-06-20 1999-05-01 게리 디. 스트리트 남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질 길란텐
WO1991001143A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Stable vaccine compositions containing interleukins
US6126945A (en) * 1989-10-03 2000-10-03 Pharmacia Ab Tumor killing effects of enterotoxins, superantigens, and related compounds
JP2546447Y2 (ja) * 1989-10-23 1997-09-03 富士機工株式会社 自在継手
FR2659554B1 (fr) * 1990-03-16 1994-09-30 Oreal Composition pour le traitement cosmetique et/ou pharmaceutique des couches superieures de l'epiderme par application topique sur la peau et procede de preparation correspondant.
IT1248934B (it) * 1990-06-01 1995-02-11 Fidia Spa Membrane forate biocompatibili,processi per la loro preparazione,loro impiego come supporto per la crescita in vitro di cellule epiteliali, pelli artificiali cosi' ottenute e loro impiego nei trapianti di pelle
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
US5216004A (en) * 1990-09-13 1993-06-01 Children's Hospital Medical Center Of North California Method for preventing malaria
US5187151A (en) * 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
US5496559A (en) * 1991-04-08 1996-03-05 Sumitomo Pharmaceuticals Company, Limited Porous solid formulations containing proteinaceous physiologically active substances
US5314874A (en) * 1991-04-19 1994-05-24 Koken Co., Ltd. Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen
US5563124A (en) * 1991-04-22 1996-10-08 Intermedics Orthopedics/ Denver, Inc. Osteogenic product and process
JPH06500802A (ja) * 1991-06-14 1994-01-27 アムジエン・インコーポレーテツド コラーゲンフィルムによるタンパクのドラッグ・デリバリー
US5648208A (en) * 1991-08-01 1997-07-15 Coletica Use of a collagen as solid binding substrate for a ligand capable of reacting specifically with an element to be detected in a biological medium, reactant and implementation
US5679348A (en) * 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
US5428011A (en) * 1992-06-16 1995-06-27 Procyon Biopharma, Inc. Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma
WO1994000484A1 (en) * 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5338836A (en) * 1992-07-29 1994-08-16 American Cyanamid Company Biologically active porcine somatotropin polypeptides and methods of using the same
FR2703927B1 (fr) * 1993-04-13 1995-07-13 Coletica Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées.
US5824651A (en) * 1993-05-10 1998-10-20 Universite De Montreal Process for modification of implant surface with bioactive conjugates for improved integration
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
GB9310781D0 (en) * 1993-05-25 1993-07-14 Davis Stanley S Preparation of microparticles
JPH0767895A (ja) * 1993-06-25 1995-03-14 Sumitomo Electric Ind Ltd 抗菌性人工血管及び抗菌性手術用縫合糸
DE69407292T2 (de) * 1993-06-30 1998-06-25 Genentech Inc Verfahren zur herstellung von liposomen
US5469559A (en) * 1993-07-06 1995-11-21 Dell Usa, L.P. Method and apparatus for refreshing a selected portion of a dynamic random access memory
AU1218295A (en) * 1993-12-09 1995-06-27 Heinrich Exner Adjuvant for antigens, process for producing the same and its use
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US20030171283A1 (en) * 1994-02-28 2003-09-11 Satterlee Daniel G. Inhibin compositions and methods of enhancing production performance
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
DE4414755C2 (de) * 1994-04-27 2000-11-16 Lohmann Therapie Syst Lts Kollagenzubereitung zur gesteuerten Abgabe von Wirkstoffen, Verfahren und Verwendung
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
US5571531A (en) * 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
US5705399A (en) * 1994-05-20 1998-01-06 The Cooper Union For Advancement Of Science And Art Sensor and method for detecting predetermined chemical species in solution
US5681568A (en) * 1994-08-19 1997-10-28 Cambridge Neuroscience, Inc. Device for delivery of substances and methods of use thereof
US5679654A (en) * 1994-09-02 1997-10-21 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
ATE197765T1 (de) * 1994-10-03 2000-12-15 Us Gov Health & Human Serv Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5916790A (en) * 1995-03-03 1999-06-29 Metabolex, Inc. Encapsulation compositions, and methods
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5750146A (en) * 1995-04-28 1998-05-12 Matrix Pharmaceutical, Inc. Translucent collagen formulations with a cytotoxic drug
US5677284A (en) * 1995-06-06 1997-10-14 Regen Biologics, Inc. Charged collagen particle-based delivery matrix
CA2178541C (en) * 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
US5827937A (en) * 1995-07-17 1998-10-27 Q Med Ab Polysaccharide gel composition
US6254872B1 (en) * 1995-08-25 2001-07-03 University Of Florida Multi-subtype FIV vaccines
US5665391A (en) * 1995-10-12 1997-09-09 Spectral Diagnostics Inc. Cultured, full-thickness integument substitutes based on three-dimensional matrix membranes
US5965125A (en) * 1995-10-25 1999-10-12 Transkaryotic Therapies, Inc. Hybrid matrix implants and explants
US5888497A (en) * 1996-04-03 1999-03-30 The Rogosin Institute Agarose coated agarose beads containing cancer cells that produce material which suppresses cancer cell proliferation
CA2217134A1 (en) * 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
JPH10139670A (ja) * 1996-11-11 1998-05-26 Terukuni Yakida インターロイキン１２誘導物質及び医薬組成物
AU6019898A (en) * 1997-01-09 1998-08-03 Cohesion Technologies, Inc. Devices for tissue repair and methods for preparation and use thereof
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
JP2001518455A (ja) * 1997-09-30 2001-10-16 セル−サイ・コーポレーシヨン 単純疱疹ウイルスの処置のための免疫原性の複合ポリペプチド
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
EP1078639A4 (de) * 1998-05-22 2004-10-06 Sumitomo Pharma Stabile genherstellung
WO2000015199A1 (fr) * 1998-09-10 2000-03-23 Sumitomo Pharmaceuticals Company, Limited Preparation de liberation prolongee de medicament a effet durable
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
US6544785B1 (en) * 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6689153B1 (en) * 1999-04-16 2004-02-10 Orthopaedic Biosystems Ltd, Inc. Methods and apparatus for a coated anchoring device and/or suture
US6486134B2 (en) * 1999-09-17 2002-11-26 Leadergene Limited Gene treatment to enhance feed efficiency and growth rate of livestock
US6551598B2 (en) * 2000-01-21 2003-04-22 Merial Vaccination against canine herpesvirosis and vaccines therefor
JP5118285B2 (ja) * 2000-06-20 2013-01-16 大日本住友製薬株式会社 オリゴヌクレオチド導入製剤
PT1313415E (pt) * 2000-08-30 2008-11-25 Univ Johns Hopkins Dispositivos para entrega intra-ocular de fármacos
AU784975B2 (en) * 2000-10-11 2006-08-10 Sumitomo Chemical Company, Limited DNA-binding protein YB-1-containing collagen accumulation inhibitors
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
NZ530550A (en) * 2001-09-11 2004-11-26 Smart Drug Systems Inc Preparation of sustained release pharmaceutical composition
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
CA2474292A1 (en) * 2002-01-24 2003-07-31 Smart Drug Systems Inc Sustained release pharmaceutical composition
JPWO2004026343A1 (ja) * 2002-09-20 2006-01-12 住友製薬株式会社 部位特異的遺伝子変換促進剤および遺伝子疾患治療剤

Also Published As

Publication number Publication date
KR100574216B1 (ko) 2006-04-27
US20110217366A1 (en) 2011-09-08
AU7238598A (en) 1998-12-11
CA2290696C (en) 2010-09-14
CA2290696A1 (en) 1998-11-26
DE69836268T2 (de) 2007-05-31
TW586934B (en) 2004-05-11
NZ500967A (en) 2001-09-28
ATE343396T1 (de) 2006-11-15
KR20010012769A (ko) 2001-02-26
AU740133B2 (en) 2001-11-01
WO1998052605A1 (en) 1998-11-26
EP0983088B1 (de) 2006-10-25
BR9809656A (pt) 2000-07-11
EP0983088A1 (de) 2000-03-08
CN1150033C (zh) 2004-05-19
CN1263470A (zh) 2000-08-16

Similar Documents

Publication Publication Date Title
DE69836268D1 (de) Immunverstärkende Zusammensetzung in fester Verabreichungsform mit Kollagen oder Polydimethylsiloxan als Trägersubstanzen
DE69431404D1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
ATE160787T1 (de) Verfahren zur herstellung von hefe-glucanen
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
DE69724970D1 (de) Verfahren zur behandlung von hypersensitivität typ i unter verwendung von monophosphoryl-lipid a
ATE203413T1 (de) IMPFSTOFFE BESTEHEND AUS PROTEIN- ODER PEPTID- ßCOCHLEATENß UND DEREN VERWENDUNG ZUR IMMUNISIERUNG
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
DK0480949T4 (da) Fremstilling af virusvaccine
IL139601A0 (en) Compositions and methods of modulating an immune response to an antigen
ATE322285T1 (de) Verfahren zur induktion der zellulären immunantwort und parenterale impfstoff- zusammensetzungen dazu
DE69833455D1 (de) Methoden und zusammensetzungen zur erhöhung der immunantwort und zur herstellung von in-vitro monoklonalen antikörpern (mabs)
DE3785033T2 (de) Verfahren zum Erhalten von immunregulierenden Faktoren mittels Säugetierimmunisierung.
ATE310750T1 (de) Verotoxin b untereinheit zur immunisierunug
DE68917138T2 (de) Toleranzinduktion gegenüber einem fremdantigen.
DE60025945D1 (de) Herstellung von antikörpern in mammarsekreten von zuchttieren
ATE318300T1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
ATE300314T1 (de) Zusammensetzung und verfahren zur immunisierung gegen ein oder mehrere antigene mittels verschiedener rekombinanter vektoren
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.
FI883765A (fi) Antikroppar mot biologiskt aktiva polypeptider och deras anvaendning vid diagnostiska foerfaranden.
RU97105225A (ru) Способ стимуляции иммунного ответа in vitro
MX170792B (es) Composicion de liberacion sostenida

Legal Events

Date Code Title Description
8364 No opposition during term of opposition